Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses

NCT00803049 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00803049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00803049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2006
Completion date
December 31, 2015
Enrollment
742 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis